Another round of pre-announcement before the release! Will Japan raise interest rates and shrink its balance sheet at the same time? Technology stocks plummeted in response to the news overnight, and the Japanese yen rose.
NHK reports that the Bank of Japan is discussing raising interest rates to 0.25%, and combined with previous analyses, the central bank may propose specific measures to reduce the balance sheet at this meeting. Will this 'double whammy' affect global markets today?
PepGen Stock Tumbles 25% Following Release of DMD Drug Data
What's Going On With Eli Lilly Today?
GSK Shingles Vaccine Cuts Dementia Risk
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
10 Health Care Stocks Whale Activity In Today's Session
$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today
CNBC Halftime Report Final Trades: Bristol-Myers Squibb, Pfizer, Textron, Oracle
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Fractyl Gets FDA Breakthrough Device Status for Revita
Tuesday Market Falls Slowly, All Eyes on AMD and MSFT | Herd on Wall St.
Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On...
Benzinga Market Summary: Merck Beats Q2 Revenue And EPS Estimates But Falls On Guidance Cut, PayPal Rises On Strong Earnings, Microsoft And AMD To Report Earnings After Market Close
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
This Is What Whales Are Betting On Eli Lilly and Co
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Pfizer in Charts: Primary Care Takes a Hit in Q2, Specialty Care and Oncology Thrive